Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan

Hassanein Mohamed; Echtay Akram Salim; Malek Rachid; Omar Mahomed; Shaikh Shehla Sajid; Ekelund Magnus; Kaplan Kadriye; Kamaruddin Nor Azmi

首页> 外文期刊>Diabetes research and clinical practice >Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan

【24h】

Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan

机译：原文：胰岛素Degludec /胰岛素Aspart的疗效和安全性分析与双相胰岛素Aspart 30：2型糖尿病患者患者的3，多期，国际，开放标签，随机治疗对目标试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aims: To compare the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) and biphasic insulin aspart 30 (BIAsp 30) before, during and after Ramadan in patients with type 2 diabetes mellitus (T2DM) who fasted during Ramadan.

机译：目的：比较胰岛素Degludec /胰岛素Aspart（IDEGASP）和双相胰岛素Aspart 30（百分比30）的疗效和安全性在斋月期间患有2型糖尿病（T2DM）的患者之前，期间和双相胰岛素Aspart 30（BiSP 30）。

著录项

来源
《Diabetes research and clinical practice》 |2018年第2018期|共9页
作者
Hassanein Mohamed; Echtay Akram Salim; Malek Rachid; Omar Mahomed; Shaikh Shehla Sajid; Ekelund Magnus; Kaplan Kadriye; Kamaruddin Nor Azmi;
展开▼
作者单位

Dubai Hosp Endocrine Dept Dubai Hlth Author Dubai U Arab Emirates;

Rafic Hariri Univ Hosp Div Endocrinol Dept Internal Med POB 5244 Beirut 28337401 Lebanon;

CHU Setif Dept Internal Med Setif 19000 Algeria;

Univ KwaZulu Natal Dept Endocrinol &

Diabet Durban South Africa;

Prince Aly Khan Hosp Dept Endocrinol Bombay Maharashtra India;

Novo Nordisk AS Vandtaarnsvej 114 DK-2860 Soborg Denmark;

Novo Nordisk AS Vandtaarnsvej 114 DK-2860 Soborg Denmark;

Natl Univ Malaysia UKM Med Ctr Jalan Yaacob Latif Bandar Tun Razal Cheras Kuala Lu Malaysia;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词
Insulin degludec/insulin aspart; Biphasic insulin aspart 30; Type 2 diabetes; Ramadan fasting; Hypoglycaemia;

机译：胰岛素Degledec /胰岛素Aspart;双相胰岛素Aspart 30;2型糖尿病;斋月禁食;低血糖;

相似文献

外文文献
中文文献
专利

1. Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan [J] . Hassanein Mohamed, Echtay Akram Salim, Malek Rachid, Diabetes research and clinical practice . 2018,第期

机译：原文：胰岛素Degludec /胰岛素Aspart的疗效和安全性分析与双相胰岛素Aspart 30：2型糖尿病患者患者的3，多期，国际，开放标签，随机治疗对目标试验
2. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: A 26-week, randomised, treat-to-target trial [J] . Kaneko Shizuka, Chow Francis, Choi Dong Seop, Diabetes research and clinical practice . 2015,第1期

机译：在基础或预混合/预混合胰岛素控制不充分的亚洲2型糖尿病患者中，地格曲胰岛素/门冬胰岛素与双相门冬胰岛素30对比：一项为期26周，针对治疗目标的随机试验
3. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: A phase 3a, randomized, treat-to-target trial [J] . Fulcher,G.R., Christiansen,J.S., Bantwal,G., Diabetes care . 2014,第8期

机译：未控制，经胰岛素治疗的2型糖尿病中地格曲松/门冬胰岛素和双相门冬胰岛素30的比较：A期3a，随机，靶向治疗
4. A randomized, open-label, intervention study to evaluate the effect of diet composition on weight gain in obese, type 2 diabetes patients receiving intensive insulin therapy. [D] . Villareal, Roland. 2008

机译：一项随机，开放标签，干预性研究，以评估饮食结构对接受强化胰岛素治疗的肥胖2型糖尿病患者体重增加的影响。
5. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III open‐label 2:1 randomized treat‐to‐target trial [O] . Wenying Yang, Jianhua Ma, Tianpei Hong, -1

机译：地格曲胰岛素/门冬胰岛素与双相门冬胰岛素30在中国2型糖尿病成年人中的疗效和安全性：III期开放标签2：1随机针对治疗的试验
6. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: A 26-week, randomised, treat-to-target trial [O] . ??? 2015

机译：门冬胰岛素/门冬胰岛素与门冬胰岛素30相比，亚洲2型糖尿病患者基础或前/自混胰岛素控制不当：一项为期26周的随机，治疗目标试验

Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan

摘要

著录项

相似文献

相关主题

期刊订阅